CLINICAL RESEARCH & EVIDENCE
[1] Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." The New England Journal of Medicine (NEJM), 2023; 389:514-526. DOI: 10.1056/NEJMoa2301972.
Foundational trial demonstrating a mean weight reduction of 24.2% at 48 weeks via synergistic GLP-1, GIP, and Glucagon receptor activation.
[2] Rosenstock J, et al. "Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for type 2 diabetes: a randomised, double-blind, 24-week, phase 2 trial." The Lancet, 2023; 402(10401):529-544.
Clinical evaluation of glycemic control and dose-dependent weight loss in metabolic research subjects.
[3] TRIUMPH Phase 3 Program. Eli Lilly and Company. "A Study of Retatrutide (LY3437943) in Participants with Obesity (TRIUMPH-1)." ClinicalTrials.gov Identifier: NCT05882019 / NCT05882045.
Ongoing 2026 multi-center trials evaluating long-term efficacy and safety across diverse metabolic cohorts.
Vitalyn Biotech Ltd | Company No: 16875620 | Registered Office: 25 Parker Crescent, Sawtry, Huntingdon, PE28 5WG.